NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020. Paul Brennan, NervGen's President & CEO, stated, "During this past quarter, we continued working to complete the IND enabling studies...
2020-11-19 8:30 AM EST
NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer's Disease Program and Renews Business Advisory Relationship with Brian McAlister
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained George Perry, PhD, the current and founding Editor-in-Chief of the Journal of Alzheimer's Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas,...
2020-11-10 8:30 AM EST
NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company's Board of Directors. Separately, NervGen announced that they were advised by its clinical research organization of a logistical delay in obtaining...
2020-10-28 8:30 AM EDT
NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-Dilutive Funding Sources For NVG-291
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Davis, MD, FACS, FRCS (Hon.), Colonel (Ret.), formerly Director of the U.S. Combat Casualty Care Research Program, to help NervGen identify,...
2020-10-19 8:30 AM EDT
NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-291, in three primary indications: multiple sclerosis, spinal cord injury and Alzheimer's disease. The NVG-291 development program is planned as follows:...
2020-10-01 7:56 PM EDT
NervGen Pharma Announces Annual General Meeting and Company Update to Be Held on September 30, 2020
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will host its annual general meeting of shareholders (the "AGM") on Wednesday, September 30, 2020 at 2:00 p.m. PDT, as previously advised in the Company's Notice of Meeting filed with the Canadian...
2020-09-22 5:26 PM EDT
NervGen Pharma Announces Departure of Chief Operating Officer
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Lloyd Mackenzie has resigned from his position as Chief Operating Officer effective October 2, 2020, in order to assume the President position of a private company not related to the focus of NervGen....
2020-09-10 8:30 AM EDT
NervGen Pharma Reports Second Quarter 2020 Results
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the second quarter ended June 30, 2020. Paul Brennan, NervGen's President & CEO, stated, "We remain very excited about the potential of our technology to treat nerve damage, whether as...
2020-08-21 8:30 AM EDT
NervGen Pharma Corp. Completes $6.45 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that today it has closed its previously announced "best efforts" public offering of 3,685,714 units of the Company ("Units") at a price of $1.75 per Unit for aggregate gross proceeds of $6,450,000 (the "Offering"). The...
2020-08-10 9:13 AM EDT
NervGen Pharma Corp. Announces Upsizing of Financing and Filing of Amended and Restated Prospectus Supplement
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that it has increased the size of its previously announced common share offering. The Company intends to issue up to 3,685,714 units of the Company ("Units") at a price of $1.75 per Unit for aggregate gross proceeds of...
2020-08-04 8:30 AM EDT
NervGen Pharma Corp. Announces Filing of Prospectus Supplement
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announces that the Company has filed a prospectus supplement (the "Prospectus Supplement") to the Company's short form base shelf prospectus dated January 2, 2020 (the "Base Shelf Prospectus") in connection with its...
2020-07-30 8:30 AM EDT
NervGen Pharma Announces Pricing of Public Offering
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has priced its previously announced offering of equity securities (the "Offering"). Pursuant to the Offering, NervGen intends to issue units of the Company (the "Units") at a price of $1.75 per...
2020-07-27 8:30 AM EDT
NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Dr. Jerry Silver of Case Western Reserve University ("CWRU") in Cleveland, Ohio, has been awarded a research grant by the State of Ohio to conduct preclinical studies in spinal cord injury in collaboration...
2020-06-22 8:15 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 225,000 incentive stock options to Directors, Officers and consultants exercisable at a price of $2.70 per share for a period of five years and that vest equally every three months...
2020-06-03 4:30 PM EDT
NervGen Pharma Reports First Quarter 2020 Results
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the first quarter ended March 31, 2020. Paul Brennan, NervGen's President & CEO, stated, "We continue to generate encouraging preclinical data to support our programs to bring...
2020-06-01 4:43 PM EDT
NervGen Pharma Corp. Closes Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce that it has closed a non-brokered private placement of 1,806,827 units of the Company at a price of CAD$1.25 per unit, for aggregate gross proceeds to the Company of CAD$2,258,534. "We appreciate the...
2020-05-20 4:13 PM EDT
NervGen Pharma Reports 2019 Year End Results
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2019. Paul Brennan, NervGen's President & CEO, stated, "2019 was an important year for NervGen during which we completed our Initial Public Offering ("IPO")...
2020-04-29 5:47 PM EDT
NervGen Pharma Provides a Corporate Update in Response to the COVID-19 Pandemic; Announces Upcoming Presentation at Solebury Trout Virtual Investor Conference on April 7th
Vancouver, British Columbia--(Newsfile Corp. - April 6, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided an update on its business in response to the COVID-19 global crisis. Paul Brennan, NervGen's President & CEO, stated, "In response to the global outbreak of COVID-19, NervGen has taken, and will continue to take...
2020-04-06 5:15 PM EDT
NervGen Pharma Provides a Development Update on Its Lead Product NVG-291
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today is providing an update to its development plan for its lead program, NVG-291. These changes are the result of a number of factors, including feedback from the United States Food and Drug Administration (the "FDA") on the recently...
2020-02-26 6:00 PM EST
NervGen Pharma Appoints Bill Adams as Chief Financial Officer
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of Chief Financial Officer effective immediately. Mr. Adams replaces Mr. Robert Pilz who will continue to formally support the Company as a consultant....
2020-02-24 8:00 AM EST